FGFR1 and chronic myelogenous leukemia, BCR-ABL1 positive: Development of more potent TKIs, such as the broad-spectrum ponatinib, active against resistant mutations of FLT3 and BCR-ABL1 in acute and chronic myeloid leukemia, respectively, may be of future clinical benefit in FGFR1 MPN [28–30].